Circulating microparticles are prognostic biomarkers in advanced non-small cell lung cancer patients

被引：21

作者：

Wang, Chin-Chou ^{[1
,2
,3
]}

Tseng, Chia-Cheng ^{[1
,4
]}

Chang, Huang-Chih ^{[1
,4
]}

Huang, Kuo-Tung ^{[1
,4
]}

Fang, Wen-Feng ^{[1
]}

Chen, Yu-Mu ^{[1
]}

Yang, Cheng-Ta ^{[5
]}

Hsiao, Chang-Chun ^{[4
,6
,7
]}

Lin, Meng-Chih ^{[1
]}

Ho, Chi-Kung ^{[2
]}

Yip, Hon-Kan ^{[6
,7
,8
,9
,10
,11
]}

机构：

[1] Chang Gung Univ, Kaohsiung Chang Gung Mem Hosp, Coll Med, Div Pulm & Crit Care Med,Dept Internal Med, Kaohsiung, Taiwan

[2] Kaohsiung Med Univ, Dept Publ Hlth, Kaohsiung, Taiwan

[3] Chang Gung Univ Sci & Technol, Dept Resp Care, Chiayi Campus, Chiayi, Taiwan

[4] Chang Gung Univ, Grad Inst Clin Med Sci, Coll Med, Kaohsiung, Taiwan

[5] Chang Gung Univ, Chang Gung Mem Hosp, Dept Pulm & Crit Care Med, Coll Med, Taoyuan, Taiwan

[6] Kaohsiung Chang Gung Mem Hosp, Ctr Shockwave Med & Tissue Engn, Kaohsiung, Taiwan

[7] Chang Gung Univ, Coll Med, Kaohsiung, Taiwan

[8] Kaohsiung Chang Gung Mem Hosp, Dept Internal Med, Div Cardiol, Kaohsiung, Taiwan

[9] China Med Univ, China Med Univ Hosp, Dept Med Res, Taichung, Taiwan

[10] Asia Univ, Dept Nursing, Taichung, Taiwan

[11] Kaohsiung Chang Gung Mem Hosp, Inst Translat Res Biomed, Kaohsiung, Taiwan

来源：

ONCOTARGET | 2017年 / 8卷 / 44期

关键词：

advanced non-small cell lung cancer; microparticles; disease control; disease progression; PLATELET-DERIVED MICROPARTICLES; SHED MEMBRANE MICROPARTICLES; 1ST-LINE TREATMENT; OPEN-LABEL; CHEMOTHERAPY; ANGIOGENESIS; MORTALITY; MULTICENTER; GEFITINIB; ERLOTINIB;

D O I：

10.18632/oncotarget.18372

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We investigated whether circulating microparticles (MPs) could serve as prognostic biomarkers in non-small cell lung cancer (NSCLC) patients. We enrolled 25 control subjects and 136 NSCLC patients categorized into disease-progression (DP, n=42) and disease-control (DC, n=94) groups. Flow cytometric analysis showed that levels of four types of circulating microparticles (EDAc-MPs, EDAp-MPs, PDAc-MPs and PDAp-MPs) were higher in the study patients than the control subjects (P < 0.04). DP patients showed poor initially performance status and more non-adenocarcinomas than DC patients. DC patients showed more EGFR mutations and poorer performance to targeted therapy than DP patients (P < 0.01). Three months after therapy, the levels of all four types of circulating MPs were lower in DC than DP patients (P < 0.02), and were comparable to the levels in control subjects. In addition, the levels of circulating MPs after 3 months accurately predicted one-year prognostic outcomes (P < 0.05). This study showed that circulating MPs are valuable prognostic biomarkers in advanced NSCLC patients.

引用

页码：75952 / 75967

页数：16

共 43 条

[1] Transfer of differentiation signal by membrane microvesicles harboring hedgehog morphogens [J].